Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL): Analysis of Real-life Data: "Snapshot" at 3 Years From the End of Ibrutinib ATU. A National Study of the FILO-LLC Group
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jul 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 17 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.
- 17 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018.
- 17 Jul 2018 Status changed from recruiting to active, no longer recruiting.